Skip to main content
. 2020 Jul 21;59(22):2849–2855. doi: 10.2169/internalmedicine.5159-20

Figure 1.

Figure 1.

Overall AQLQ scores during mepolizumab therapy. The overall AQLQ scores during mepolizumab therapy are shown for all patients (A), responders (B) and non-responders (C). Responders and non-responders were defined by the increase in the AQLQ score at 16 weeks from baseline (i.e., responders, 0.5<; and non-responders, ≤0.5). *p<0.05 vs. AQLQ overall score at baseline. AQLQ: Asthma Quality of Life Questionnaire